Jonathan L. Moore , FRCS1,2; Michael Green, FRCPath3; Aida Santaolalla, PhD2; Harriet Deere, FRCPath3; Richard P.T. Evans, MRCS4; Mona Elshafie, MD, FRCPath5; Anita Lavery , MD6; Damian T. McManus, MD, FRCPath7; Andrew McGuigan , MB, MRCS6; Rosalie Douglas , MD, PhD6; Joanne Horne, FRCPath8; Robert Walker , FRCS9; Hira Mir, FRCPath10; Monica Terlizzo, FRCPath10; Sivesh K. Kamarajah , MRCS5; Mieke Van Hemelrijck, PhD2; Nick Maisey, MD, FRCP11; Ailsa Sita-Lumsden, PhD, MRCP11; Sarah Ngan, PhD, FRCP11; Mark Kelly , MRes, FRCS1,2; Cara R. Baker, PhD, FRCS1,2; Sacheen Kumar , PhD, FRCS12; Jesper Lagergren , MD, PhD1,2,13; William H. Allum, MD, FRCS12; James A. Gossage, MS, FRCS1,2; Ewen A. Griffiths , MD, MFST, FRCS5; Heike I. Grabsch , MD, PhD, FRCPath14,15; Richard C. Turkington , MD, PhD6; Tim J. Underwood , PhD, FRCS9; Elizabeth C. Smyth, MD16; Rebecca C. Fitzgerald , MD, FMedSci17,18; David Cunningham , MD, FRCP, FMedSci19; Andrew R. Davies, MD, FRCS1,2; on behalf of The Oesophageal Cancer Clinical and Molecular Stratification (OCCAMS) study group, The Guy's and St Thomas' Oesophago-gastric Research Group, and The PROGRESS study group
Read Abstract: Pathologic Lymph Node Regression After Neoadjuvant Chemotherapy Predicts Recurrence and Survival in Esophageal Adenocarcinoma: A Multicenter Study in the United Kingdom
.png){kind=logo}
